452 related articles for article (PubMed ID: 17629849)
1. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Perzborn E; Kubitza D; Misselwitz F
Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
[TBL] [Abstract][Full Text] [Related]
4. [Rivaroxaban (Xarelto): efficacy and safety].
Rosencher N; Arnaout L; Chabbouh T; Bellamy L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
6. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
Chen T; Lam S
Cardiol Rev; 2009; 17(4):192-7. PubMed ID: 19525681
[TBL] [Abstract][Full Text] [Related]
8. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
9. [Summary and perspectives. Rivaroxaban].
Albaladejo P
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban: a new oral factor Xa inhibitor.
Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
Kubitza D; Becka M; Mueck W; Zuehlsdorf M
J Clin Pharmacol; 2006 Sep; 46(9):981-90. PubMed ID: 16920892
[TBL] [Abstract][Full Text] [Related]
12. [Rivaroxaban: mode of action].
Drouet L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
15. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
16. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
17. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
Kakar P; Watson T; Lip GY
Curr Opin Investig Drugs; 2007 Mar; 8(3):256-65. PubMed ID: 17408122
[TBL] [Abstract][Full Text] [Related]
18. Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Perzborn E
Hamostaseologie; 2009 Aug; 29(3):260-7. PubMed ID: 19644596
[TBL] [Abstract][Full Text] [Related]
19. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
Mousa SA
Methods Mol Biol; 2010; 663():181-201. PubMed ID: 20617418
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
ROCKET AF Study Investigators
Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
